Eisai Says Lecanemab Slows Decline in Alzheimer’s Substudy
The report says lecanemab slowed decline among Alzheimer’s patients with alpha-synuclein co-pathology in a substudy.
The report says lecanemab slowed decline among Alzheimer’s patients with alpha-synuclein co-pathology in a substudy.